STOCK TITAN

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on February 28, 2024, to report its Q4 and full-year 2023 financial results and recent portfolio execution. Interested individuals can access the webcast through the company's website or participate via telephone by registering. A replay will be available on Kiniksa's website post-event.
Positive
  • None.
Negative
  • None.

HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com


Kiniksa Pharmaceuticals will host a conference call on February 28, 2024, at 8:30 a.m. Eastern Time.

Interested individuals can access the live webcast through the Investors & Media section of Kiniksa's website at www.kiniksa.com.

Individuals can participate in the conference call via telephone by registering on the company's website. Upon registration, participants will receive a confirmation email with details on how to join the call.

Yes, a replay of the event will be available on Kiniksa's website within approximately 48 hours after the conference call.
Kiniksa Pharmaceuticals Ltd

NASDAQ:KNSA

KNSA Rankings

KNSA Latest News

KNSA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing

About KNSA

kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.